Resources from the same session
Brigatinib vs crizotinib in patients with ALK inhibitor-naive advanced ALK+ NSCLC: Updated results from the phase III ALTA-1L trial
Presenter: Ross Camidge
Session: Presidential session
Resources:
Slides
Webcast
LBA2 - TATTON expansion cohorts: A phase Ib study of osimertinib plus savolitinib in patients (pts) with EGFR-mutant, MET-positive NSCLC following disease progression on a prior EGFR-TKI
Presenter: Ji-Youn Han
Session: Presidential session
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA2
Presenter: David Planchard
Session: Presidential session
Resources:
Slides
Webcast
LBA3 - IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) + bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Ann-Lii Cheng
Session: Presidential session
Resources:
Abstract
Slides
Webcast
Invited Discussant LBA3
Presenter: Ian Chau
Session: Presidential session
Resources:
Slides
Webcast